General Information of the Compound
Compound ID |
CP0132947
|
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Compound Name |
BMN 673
Show/Hide
|
||||||||||||||||||
Synonyms |
2YQ
4pjt
9QHX048FRV
Talazoparib
Talazoparib (BMN 673)
Talazoparib [USAN:INN]
Talzenna
UNII-9QHX048FRV
Show/Hide
|
||||||||||||||||||
Structure |
|
||||||||||||||||||
Formula |
C19H14F2N6O
|
||||||||||||||||||
Molecular Weight |
380.358
|
||||||||||||||||||
Canonical SMILES |
Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1
Show/Hide
|
||||||||||||||||||
InChI |
InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1
Show/Hide
|
||||||||||||||||||
InChIKey |
HWGQMRYQVZSGDQ-HZPDHXFCSA-N
|
||||||||||||||||||
CAS |
1207456-01-6
|
||||||||||||||||||
Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
PubChem ID | |||||||||||||||||||
ChEMBL ID | |||||||||||||||||||
DrugBank ID |
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT00839, Poly [ADP-ribose] polymerase 1
Protein ID: PT01328, Poly [ADP-ribose] polymerase 2
Cell Viability or Cytotoxicity Assay
Cell Line ID | Cell Line Name | Cell Line Organism | |
CL000006 | HEK293 | Homo sapiens (Human) | 1 |
1 |
IC50 = 4.95 nM
|
TI
LI
LO
TS
|
---|
Clinical Information about the Compound